CHF16.06
4.63% today
SIX Swiss Exchange, Apr 03, 05:17 pm CET
ISIN
CH1110760852
Symbol
PPGN
Sector
Industry

PolyPeptide Target price 2025 - Analyst rating & recommendation

PolyPeptide Classifications & Recommendation:

Buy
50%
Hold
33%
Sell
17%

PolyPeptide Price Target

Target Price CHF28.97
Price CHF16.84
Potential
Number of Estimates 5
5 Analysts have issued a price target PolyPeptide 2026 . The average PolyPeptide target price is CHF28.97. This is higher than the current stock price. The highest price target is
CHF44.56 164.60%
register free of charge
, the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend PolyPeptide to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the PolyPeptide stock has an average upside potential 2026 of . Most analysts recommend the PolyPeptide stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 320.83 385.97
3.07% 20.30%
EBITDA Margin 6.94% 13.48%
312.14% 94.29%
Net Margin -5.86% 1.20%
63.62% 120.47%

5 Analysts have issued a sales forecast PolyPeptide 2025 . The average PolyPeptide sales estimate is

CHF386m
Unlock
. This is
20.51% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF415m 29.60%
Unlock
, the lowest is
CHF371m 15.83%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF321m 3.07%
2025
CHF386m 20.30%
Unlock
2026
CHF453m 17.45%
Unlock
2027
CHF515m 13.64%
Unlock
2028
CHF601m 16.66%
Unlock

5 Analysts have issued an PolyPeptide EBITDA forecast 2025. The average PolyPeptide EBITDA estimate is

CHF52.0m
Unlock
. This is
135.42% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF71.3m 222.73%
Unlock
, the lowest is
CHF42.5m 92.50%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF22.3m 318.66%
2025
CHF52.0m 133.73%
Unlock
2026
CHF83.8m 61.06%
Unlock
2027
CHF108m 28.64%
Unlock
2028
CHF147m 36.66%
Unlock

EBITDA Margin

2024 6.94% 312.14%
2025
13.48% 94.29%
Unlock
2026
18.49% 37.17%
Unlock
2027
20.93% 13.20%
Unlock
2028
24.51% 17.10%
Unlock

3 PolyPeptide Analysts have issued a net profit forecast 2025. The average PolyPeptide net profit estimate is

CHF4.7m
Unlock
. This is
124.72% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF6.9m 136.74%
Unlock
, the lowest is
CHF2.6m 114.04%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF-18.8m 62.50%
2025
CHF4.7m 124.72%
Unlock
2026
CHF20.6m 342.15%
Unlock
2027
CHF39.4m 91.83%
Unlock

Net Margin

2024 -5.86% 63.62%
2025
1.20% 120.47%
Unlock
2026
4.54% 278.33%
Unlock
2027
7.66% 68.72%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF -0.57 0.14
62.50% 124.56%
P/E 119.49
EV/Sales 1.50

3 Analysts have issued a PolyPeptide forecast for earnings per share. The average PolyPeptide EPS is

CHF0.14
Unlock
. This is
124.56% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF0.21 136.84%
Unlock
, the lowest is
CHF0.08 114.04%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF-0.57 62.50%
2025
CHF0.14 124.56%
Unlock
2026
CHF0.62 342.86%
Unlock
2027
CHF1.20 93.55%
Unlock

P/E ratio

Current -29.76 49.70%
2025
119.49 501.51%
Unlock
2026
27.03 77.38%
Unlock
2027
14.09 47.87%
Unlock

Based on analysts' sales estimates for 2025, the PolyPeptide stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.81 44.65%
2025
1.50 16.99%
Unlock
2026
1.28 14.86%
Unlock
2027
1.13 12.00%
Unlock
2028
0.97 14.28%
Unlock

P/S ratio

Current 1.74 46.08%
2025
1.44 17.02%
Unlock
2026
1.23 14.86%
Unlock
2027
1.08 12.00%
Unlock
2028
0.92 14.29%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today